BONDRONAT

Bondronat Adverse Events Reported to the FDA Over Time

How are Bondronat adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Bondronat, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Bondronat is flagged as the suspect drug causing the adverse event.

Most Common Bondronat Adverse Events Reported to the FDA

What are the most common Bondronat adverse events reported to the FDA?

Osteonecrosis	166 (18.89%)
Metastases To Bone	22 (2.5%)
Osteomyelitis	22 (2.5%)
Bone Disorder	17 (1.93%)
Tooth Extraction	16 (1.82%)
Metastases To Liver	14 (1.59%)
Abdominal Pain Upper	11 (1.25%)
Impaired Healing	11 (1.25%)
Abscess	9 (1.02%)
Chest Pain	9 (1.02%)
Diarrhoea	9 (1.02%)
	Show More
Dyspnoea	9 (1.02%)
Pyrexia	9 (1.02%)
Death	8 (.91%)
General Physical Health Deteriorati...	8 (.91%)
Malignant Neoplasm Progression	8 (.91%)
Pain In Jaw	8 (.91%)
Infection	7 (.8%)
Jaw Disorder	7 (.8%)
Pain	7 (.8%)
Vomiting	7 (.8%)
Blood Pressure Decreased	6 (.68%)
Chills	6 (.68%)
Disease Progression	6 (.68%)
Heart Rate Increased	6 (.68%)
Liver Disorder	6 (.68%)
Polyneuropathy	6 (.68%)
Swelling	6 (.68%)
Tachypnoea	6 (.68%)
Anaemia	5 (.57%)
Bone Pain	5 (.57%)
Breast Cancer	5 (.57%)
Deep Vein Thrombosis	5 (.57%)
Erythema	5 (.57%)
Gastric Disorder	5 (.57%)
Hypocalcaemia	5 (.57%)
Myalgia	5 (.57%)
Nausea	5 (.57%)
Oral Disorder	5 (.57%)
Paraesthesia	5 (.57%)
Tooth Disorder	5 (.57%)
Toothache	5 (.57%)
Actinomycosis	4 (.46%)
Asthenia	4 (.46%)
Blood Creatinine Increased	4 (.46%)
Colon Cancer	4 (.46%)
Epistaxis	4 (.46%)
Extravasation	4 (.46%)
Fatigue	4 (.46%)
Headache	4 (.46%)
Hypercalcaemia	4 (.46%)
Incorrect Route Of Drug Administrat...	4 (.46%)
Iridocyclitis	4 (.46%)
Macular Oedema	4 (.46%)
Oral Surgery	4 (.46%)
Osteitis	4 (.46%)
Periodontitis	4 (.46%)
Primary Sequestrum	4 (.46%)
Pulmonary Embolism	4 (.46%)
Stomatitis	4 (.46%)
Tachycardia	4 (.46%)
Visual Impairment	4 (.46%)
Arrhythmia	3 (.34%)
Arthralgia	3 (.34%)
Bacterial Infection	3 (.34%)
Biopsy Site Unspecified Abnormal	3 (.34%)
Cough	3 (.34%)
Dizziness	3 (.34%)
Drug Interaction	3 (.34%)
Dysphagia	3 (.34%)
Eye Pain	3 (.34%)
Gastrointestinal Haemorrhage	3 (.34%)
Haemoglobin Decreased	3 (.34%)
Hypertension	3 (.34%)
Hypomagnesaemia	3 (.34%)
Inflammation	3 (.34%)
Jaw Operation	3 (.34%)
Lenticular Opacities	3 (.34%)
Loose Tooth	3 (.34%)
Metabolic Acidosis	3 (.34%)
Multi-organ Failure	3 (.34%)
Neoplasm Malignant	3 (.34%)
Oral Mucosa Erosion	3 (.34%)
Osteoarthritis	3 (.34%)
Osteotomy	3 (.34%)
Pneumonia	3 (.34%)
Renal Failure	3 (.34%)
Abdominal Discomfort	2 (.23%)
Abdominal Pain	2 (.23%)
Abdominal Symptom	2 (.23%)
Abscess Jaw	2 (.23%)
Angina Pectoris	2 (.23%)
Arthritis	2 (.23%)
Body Temperature Increased	2 (.23%)
Bone Lesion	2 (.23%)
Bone Operation	2 (.23%)
Cardiotoxicity	2 (.23%)
Chest Discomfort	2 (.23%)
Condition Aggravated	2 (.23%)
Dementia	2 (.23%)
Dental Operation	2 (.23%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Bondronat, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Bondronat is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Bondronat

What are the most common Bondronat adverse events reported to the FDA?

Bone Disorders	218 (24.8%)
Infections - Pathogen Unspecified	58 (6.6%)
Metastases	38 (4.32%)
Gastrointestinal Signs	33 (3.75%)
Head And Neck Therapeutic Procedure...	27 (3.07%)
Dental And Gingival Conditions	24 (2.73%)
Respiratory	20 (2.28%)
Neurological	19 (2.16%)
Cardiac And Vascular Investigations	15 (1.71%)
Oral Soft Tissue Conditions	15 (1.71%)
Bone, Calcium, Magnesium And Phosph...	12 (1.37%)
	Show More
Miscellaneous And Site Unspecified ...	11 (1.25%)
Tissue	11 (1.25%)
Epidermal And Dermal Conditions	10 (1.14%)
Body Temperature Conditions	9 (1.02%)
Gastrointestinal Motility And Defec...	9 (1.02%)
Bacterial Infectious	8 (.91%)
Fatal Outcomes	8 (.91%)
Hepatic And Hepatobiliary	8 (.91%)
Joint	8 (.91%)
Ocular Infections, Irritations And ...	8 (.91%)
Anemias Nonhemolytic And Marrow Dep...	7 (.8%)
Cardiac Arrhythmias	7 (.8%)
Gastrointestinal Conditions	7 (.8%)
Investigations, Imaging And Histopa...	7 (.8%)
Muscle	7 (.8%)
Therapeutic And Nontherapeutic Effe...	7 (.8%)
Bone And Joint Therapeutic Procedur...	6 (.68%)
Breast Neoplasms Malignant And Unsp...	6 (.68%)
Embolism And Thrombosis	6 (.68%)
Eye	6 (.68%)
Headaches	6 (.68%)
Peripheral Neuropathies	6 (.68%)
Physical Examination Topics	6 (.68%)
Renal Disorders	6 (.68%)
Administration Site Reactions	5 (.57%)
Gastrointestinal Hemorrhages	5 (.57%)
Anterior Eye Structural Change, Dep...	4 (.46%)
Coronary Artery	4 (.46%)
Gastrointestinal Neoplasms Malignan...	4 (.46%)
Injuries	4 (.46%)
Medication Errors	4 (.46%)
Procedural And Device Related Injur...	4 (.46%)
Pulmonary Vascular	4 (.46%)
Renal And Urinary Tract Investigati...	4 (.46%)
Therapeutic Procedures And Supporti...	4 (.46%)
Upper Respiratory Tract Disorders	4 (.46%)
Vision	4 (.46%)
Acid-base	3 (.34%)
Bone And Joint Injuries	3 (.34%)
Disturbances In Thinking	3 (.34%)
Gastrointestinal Ulceration And Per...	3 (.34%)
Hematology Investigations	3 (.34%)
Movement Disorders	3 (.34%)
Musculoskeletal And Connective Tiss...	3 (.34%)
Skin Appendage Conditions	3 (.34%)
Vascular Hypertensive	3 (.34%)
White Blood Cell	3 (.34%)
Allergic Conditions	2 (.23%)
Cardiac Disorder Signs	2 (.23%)
Electrolyte And Fluid Balance Condi...	2 (.23%)
Encephalopathies	2 (.23%)
Exocrine Pancreas Conditions	2 (.23%)
Iron And Trace Metal Metabolism	2 (.23%)
Lipid Metabolism	2 (.23%)
Mental Impairment	2 (.23%)
Nephropathies	2 (.23%)
Ocular Structural Change, Deposit A...	2 (.23%)
Personality Disorders	2 (.23%)
Plasma Cell Neoplasms	2 (.23%)
Seizures	2 (.23%)
Skin And Subcutaneous Tissue	2 (.23%)
Sleep Disorders	2 (.23%)
Tendon, Ligament And Cartilage	2 (.23%)
Thyroid Gland	2 (.23%)
Toxicology And Therapeutic Drug Mon...	2 (.23%)
Urinary Tract Signs	2 (.23%)
Anxiety Disorders	1 (.11%)
Bronchial Disorders	1 (.11%)
Central Nervous System Vascular	1 (.11%)
Coagulopathies And Bleeding Diathes...	1 (.11%)
Fractures	1 (.11%)
Fungal Infectious	1 (.11%)
Gastrointestinal	1 (.11%)
Hearing	1 (.11%)
Hemolyses And Related Conditions	1 (.11%)
Hypothalamus And Pituitary Gland	1 (.11%)
Inner Ear And Viiith Cranial Nerve	1 (.11%)
Lymphatic Vessel	1 (.11%)
Metabolic, Nutritional And Blood Ga...	1 (.11%)
Neoplasm Related Morbidities	1 (.11%)
Pleural	1 (.11%)
Protein And Chemistry Analyses	1 (.11%)
Respiratory Tract Therapeutic Proce...	1 (.11%)
Skin Vascular Abnormalities	1 (.11%)
Viral Infectious	1 (.11%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Bondronat, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Bondronat is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.